The role of PTEN in tumor angiogenesis

Journal of Oncology

Volumn , Issue , 2012, Pages

  Rodriguez, Stéphane ^a   Huynh Do, Uyen ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; SORAFENIB; STREPTOZOCIN; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; BREAST CANCER; CANCER GENE THERAPY; CANCER HORMONE THERAPY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; LOSS OF FUNCTION MUTATION; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHYSIOLOGICAL PROCESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; TUMOR RESISTANCE;

EID: 81555220913     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/141236     Document Type: Review

References (122)

1. Carmeliet P., Mechanisms of angiogenesis and arteriogenesis Nature Medicine 2000 6 4 389 395 (Pubitemid 30208155)
2. Jakobsson L., Franco C. A., Bentley K., Collins R. T., Ponsioen B., Aspalter I. M., Rosewell I., Busse M., Thurston G., Medvinsky A., Schulte-Merker S., Gerhardt H., Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting Nature Cell Biology 2010 12 10 943 953
3. Jain R. K., Molecular regulation of vessel maturation Nature Medicine 2003 9 6 685 693 (Pubitemid 36749217)
4. Dvorak H. F., Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing The New England Journal of Medicine 1986 315 26 1650 1659 (Pubitemid 17052899)
5. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risaut W., Nagy A., Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 1996 380 6573 435 439 (Pubitemid 26102719)
6. Olsson A. K., Dimberg A., Kreuger J., Claesson-Welsh L., VEGF receptor signallingin control of vascular function Nature Reviews Molecular Cell Biology 2006 7 5 359 371
7. Dumont D. J., Gradwohl G., Fong G. H., Puri M. C., Gertsenstein M., Auerbach A., Breitman M. L., Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo Genes and Development 1994 8 16 1897 1909 (Pubitemid 24273890)
8. Sato T. N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y., Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation Nature 1995 376 6535 70 74
9. Daly C., Wong V., Burova E., Wei Y., Zabski S., Griffiths J., Lai K. M., Lin H. C., Ioffe E., Yancopoulos G. D., Rudge J. S., Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) Genes and Development 2004 18 9 1060 1071 (Pubitemid 38620245)
10. Kuijper S., Turner C. J., Adams R. H., Regulation of angiogenesis by Eph-ephrin interactions Trends in Cardiovascular Medicine 2007 17 5 145 151 (Pubitemid 46898841)
11. Stephen L. J., Fawkes A. L., Verhoeve A., Lemke G., Brown A., A critical role for the EphA3 receptor tyrosine kinase in heart development Developmental Biology 2007 302 1 66 79 (Pubitemid 46096924)
12. Wilkinson D. G., Multiple roles of Eph receptors and ephrins in neural development Nature Reviews Neuroscience 2001 2 3 155 164 (Pubitemid 33673369)
13. Steinle J. J., Meininger C. J., Forough R., Wu G., Wu M. H., Granger H. J., Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway Journal of Biological Chemistry 2002 277 46 43830 43835 (Pubitemid 36157804)
14. Wang H. U., Chen Z. F., Anderson D. J., Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 Cell 1998 93 5 741 753 (Pubitemid 28257581)
15. Sawamiphak S., Seidel S., Essmann C. L., Wilkinson G. A., Pitulescu M. E., Acker T., Acker-Palmer A., Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis Nature 2010 465 7297 487 491
16. Oike Y., Ito Y., Hamada K., Zhang X. Q., Miyata K., Arai F., Inada T., Araki K., Nakagata N., Takeya M., Kisanuki Y. Y., Yanagisawa M., Gale N. W., Suda T., Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells Blood 2002 100 4 1326 1333 (Pubitemid 34864288)
17. Wang G. L., Jiang B. H., Rue E. A., Semenza G. L., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proceedings of the National Academy of Sciences of the United States of America 1995 92 12 5510 5514
18. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J. M., Lane W. S., Kaelin W. G., HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 2001 292 5516 464 468 (Pubitemid 32335941)
19. Baldewijns M. M., van Vlodrop I. J. H., Vermeulen P. B., Soetekouw P. M. M. B., van Engeland M., de Brune A. P., VHL and HIF signalling in renal cell carcinogenesis Journal of Pathology 2010 221 2 125 138
20. Vihanto M. M., Plock J., Erni D., Frey B. M., Frey F. J., Huynh-Do U., Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin FASEB Journal 2005 19 12 1689 1691 (Pubitemid 41429531)
21. Xu J., Rodriguez D., Petitclerc E., Kim J. J., Hangai M., Yuen S. M., Davis G. E., Brooks P. C., Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo Journal of Cell Biology 2001 154 5 1069 1079 (Pubitemid 34286185)
22. Whitelock J. M., Murdoch A. D., Iozzo R. V., Underwood P. A., The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases Journal of Biological Chemistry 1996 271 17 10079 10086 (Pubitemid 26131567)
23. Marsh D. J., Coulon V., Lunetta K. L., Rocca-Serra P., Dahia P. L. M., Zheng Z., Liaw D., Caron S., Duboué B., Lin A. Y., Richardson A. L., Bonnetblanc J. M., Bressieux J. M., Cabarrot-Moreau A., Chompret A., Demange L., Eeles R. A., Yahanda A. M., Fearon E. R., Fricker J. P., Gorlin R. J., Hodgson S. V., Huson S., Lacombe D., LePrat F., Odent S., Toulouse C., Olopade O. I., Sobol H., Tishler S., Woods C. G., Robinson B. G., Weber H. C., Parsons R., Peacocke M., Longy M., Eng C., Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation Human Molecular Genetics 1998 7 3 507 515 (Pubitemid 28120643)
24. Trotman L. C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., Pavletich N. P., Carver B. S., Cordon-Cardo C., Erdjument-Bromage H., Tempst P., Chi S. G., Kim H. J., Misteli T., Jiang X., Pandolfi P. P., Ubiquitination regulates PTEN nuclear import and tumor suppression Cell 2007 128 1 141 156 (Pubitemid 46048885)
25. Zhou X. P., Marsh D. J., Morrison C. D., Chaudhury A. R., Maxwell M., Reifenberger G., Eng C., Germline inactivation of PTEN and dysregulation of the phosphoinositol-3- kinase/Akt pathway cause human Lhermitte-Duclos disease in adults American Journal of Human Genetics 2003 73 5 1191 1198 (Pubitemid 37414231)
26. Zhou X. P., Hampel H., Thiele H., Gorlin R. J., Hennekam R. C. M., Parisi M., Winter R. M., Eng C., Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes The Lancet 2001 358 9277 210 211 (Pubitemid 32718548)
27. Varga E. A., Pastore M., Prior T., Herman G. E., McBride K. L., The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly Genetics in Medicine 2009 11 2 111 117
28. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 (Pubitemid 26272076)
29. Chun Y. S., Kim M. S., Park J. W., Oxygen-dependent and -independent regulation of HIF-1alpha Journal of Korean Medical Science 2002 17 5 581 588
30. Kalluri R., Zeisberg M., Fibroblasts in cancer Nature Reviews Cancer 2006 6 5 392 401
31. Murakami M., Zheng Y., Hirashima M., Suda T., Morita Y., Ooehara J., Ema H., Fong G. H., Shibuya M., VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 4 658 664 (Pubitemid 351651323)
32. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R. K., McDonald D. M., Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors American Journal of Pathology 2002 160 3 985 1000 (Pubitemid 34224587)
33. Helfrich I., Edler L., Sucker A., Thomas M., Christian S., Schadendorf D., Augustin H. G., Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma Clinical Cancer Research 2009 15 4 1384 1392
34. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 1999 284 5422 1994 1998 (Pubitemid 29309448)
35. Huang X., Yamada Y., Kidoya H., Naito H., Nagahama Y., Kong L., Katoh S. Y., Li W. L., Ueno M., Takakura N., EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis Cancer Research 2007 67 20 9800 9808 (Pubitemid 47621227)
36. Kimura M., Kato Y., Sano D., Fujita K., Sakakibara A., Kondo N., Mikami Y., Tsukuda M., Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck International Journal of Oncology 2009 34 2 321 327
37. Krasnoperov V., Kumar S. R., Ley E., Li X., Scehnet J., Liu R., Zozulya S., Gill P. S., Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth American Journal of Pathology 2010 176 4 2029 2038
38. Kumar S. R., Singh J., Xia G., Krasnoperov V., Hassanieh L., Ley E. J., Scehnet J., Kumar N. G., Hawes D., Press M. F., Weaver F. A., Gill P. S., Receptor tyrosine kinase EphB4 is a survival factor in breast cancer American Journal of Pathology 2006 169 1 279 293
39. Masood R., Kumar S. R., Sinha U. K., Crowe D. L., Krasnoperov V., Reddy R. K., Zozulya S., Singh J., Xia G., Broek D., Schnthal A. H., Gill P. S., EphB4 provides survival advantage to squamous cell carcinoma of the head and neck International Journal of Cancer 2006 119 6 1236 1248 (Pubitemid 44258795)
40. Martiny-Baron G., Korff T., Schaffner F., Esser N., Eggstein S., Marmé D., Augustin H. G., Inhibition of tumor growth and angiogenesis by soluble EphB4 Neoplasia 2004 6 3 248 257 (Pubitemid 38657081)
41. Cunningham S. A., Waxham M. N., Arrate P. M., Brock T. A., Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding Journal of Biological Chemistry 1995 270 35 20254 20257
42. Gerber H. P., McMurtrey A., Kowalski J., Yan M., Keyt B. A., Dixit V., Ferrara N., Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation Journal of Biological Chemistry 1998 273 46 30336 30343 (Pubitemid 28545503)
43. Wang L., Zheng G. Z., Rui L. Z., Gregg S. R., Hozeska-Solgot A., LeTourneau Y., Wang Y., Chopp M., Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin- activated endothelial cells promote neural progenitor cell migration Journal of Neuroscience 2006 26 22 5996 6003 (Pubitemid 44318365)
44. Guan X. H., Lu X. F., Zhang H. X., Wu J. R., Yuan Y., Bao Q., Ling D. Y., Cao J. L., Phosphatidylinositol 3-kinase mediates pain behaviors induced by activation of peripheral ephrinBs/EphBs signaling in mice Pharmacology Biochemistry and Behavior 2010 95 3 315 324
45. Vanhaesebroeck B., Leevers S. J., Panayotou G., Waterfield M. D., Waterfield M. D., Phosphoinositide 3-kinases: a conserved family of signal transducers Trends in Biochemical Sciences 1997 22 7 267 272 (Pubitemid 27310948)
46. Maehama T., Taylor G. S., Dixon J. E., PTEN and myotubularin: novel phosphoinositide phosphatases Annual Review of Biochemistry 2001 70 247 279 (Pubitemid 32662211)
47. Cantley L. C., Neel B. G., New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4240 4245 (Pubitemid 29190320)
48. Gu J., Tamura M., Pankov R., Danen E. H. J., Takino T., Matsumoto K., Yamada K. M., Shc and FAK differentially regulate cell motility and directionality modulated by PTEN Journal of Cell Biology 1999 146 2 389 403 (Pubitemid 29369775)
49. Tamura M., Gu J., Matsumoto K., Aota S. I., Parsons R., Yamada K. M., Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN Science 1998 280 5369 1614 1617 (Pubitemid 28277707)
50. Raftopoulou M., Etienne-Manneville S., Self A., Nicholls S., Hall A., Regulation of cell migration by the C2 domain of the tumor suppressor PTEN Science 2004 303 5661 1179 1181 (Pubitemid 38233580)
51. Leslie N. R., Yang X., Downes C. P., Weijer C. J., PtdIns(3,4,5)P 3 -dependent and -independent roles for PTEN in the control of cell migration Current Biology 2007 17 2 115 125 (Pubitemid 46107842)
52. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S. T., Patel T., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer Gastroenterology 2007 133 2 647 658 (Pubitemid 47187346)
53. Wang X., Jiang X., Post-translational regulation of PTEN Oncogene 2008 27 41 5454 5463
54. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A. R., Ryan H. E., Johnson R. S., Jefferson A. B., Stokoe D., Giaccia A. J., Loss of PTEN facilitates HIF-1-mediated gene expression Genes and Development 2000 14 4 391 396 (Pubitemid 30131884)
55. Teichman A. V., Compérat E., Behnke S., Storz M., Moch H., Schraml P., VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma Modern Pathology 2010
56. Frew I. J., Thoma C. R., Georgiev S., Minola A., Hitz M., Montani M., Moch H., Krek W., pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation EMBO Journal 2008 27 12 1747 1757
57. Fang J., Ding M., Yang L., Liu L. Z., Jiang B. H., PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis Cellular Signalling 2007 19 12 2487 2497 (Pubitemid 47531929)
58. Tian T., Nan K. J., Wang S. H., Liang X., Lu C. X., Guo H., Wang W. J., Ruan Z. P., PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells Carcinogenesis 2010 31 7 1211 1219
59. Takei Y., Saga Y., Mizukami H., Takayama T., Ohwada M., Ozawa K., Suzuki M., Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice Molecular Cancer Therapeutics 2008 7 3 704 711 (Pubitemid 351482153)
60. Wang S., Cheng Z., Yang X., Deng K., Cao Y., Chen H., Pan L., Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma International Journal of Hematology 2010 92 1 83 94
61. Zheng H., Takahashi H., Murai Y., Cui Z., Nomoto K., Niwa H., Tsuneyama K., Takano Y., Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma Anticancer Research 2006 26 5 A 3579 3583 (Pubitemid 44701542)
62. Giovannetti E., Funel N., Peters G. J., Del Chiaro M., Erozenci L. A., Vasile E., Leon L. G., Pollina L. E., Groen A., Falcone A., Danesi R., Campani D., Verheul H. M., Boggi U., MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity Cancer Research 2010 70 11 4528 4538
63. Sekuklu S. D., Donoghue M. T. A., Spillane C., miR-21 as a key regulator of oncogenic processes Biochemical Society Transactions 2009 37, part 4 918 925
64. DeBusk L. M., Hallahan D. E., Lin P. C., Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway Experimental Cell Research 2004 298 1 167 177 (Pubitemid 38887316)
65. Findley C. M., Cudmore M. J., Ahmed A., Kontos C. D., VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt-dependent pathway to modulate Tie2 signaling Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 12 2619 2626 (Pubitemid 350158914)
66. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L. L., Cavalli F., Mazzucchelli L., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients British Journal of Cancer 2007 97 8 1139 1145 (Pubitemid 47587019)
67. Razis E., Briasoulis E., Vrettou E., Skarlos D. V., Papamichael D., Kostopoulos I., Samantas E., Xanthakis I., Bobos M., Galanidi E., Bai M., Gikonti I., Koukouma A., Kafiri G., Papakostas P., Kalogeras K. T., Kosmidis P., Fountzilas G., Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study BMC Cancer 2008 8 234
68. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., Molinari F., De Dosso S., Saletti P., Martini M., Cipani T., Marrapese G., Mazzucchelli L., Lamba S., Veronese S., Frattini M., Bardelli A., Siena S., Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS ONE 2009 4 10
69. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Research 2009 69 5 1851 1857
70. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J. B., Lecomte T., Rougier P., Lievre A., Landi B., Boige V., Ducreux M., Ychou M., Bibeau F., Bouché O., Reid J., Stone S., Penault-Llorca F., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer Journal of Clinical Oncology 2009 27 35 5924 5930
71. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., Masi G., Graziano F., Cremolini C., Rulli E., Canestrari E., Funel N., Schiavon G., Petrini I., Magnani M., Tonini G., Campani D., Floriani I., Cascinu S., Falcone A., PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer Journal of Clinical Oncology 2009 27 16 2622 2629
72. Perrone F., Lampis A., Orsenigo M., Di Bartolomeo M., Gevorgyan A., Losa M., Frattini M., Riva C., Andreola S., Bajetta E., Bertario L., Leo E., Pierotti M. A., Pilotti S., PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Annals of Oncology 2009 20 1 84 90
73. Berns K., Horlings H. M., Hennessy B. T., Madiredjo M., Hijmans E. M., Beelen K., Linn S. C., Gonzalez-Angulo A. M., Stemke-Hale K., Hauptmann M., Beijersbergen R. L., Mills G. B., van de Vijver M. J., Bernards R., A Functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 2007 12 4 395 402 (Pubitemid 47539306)
74. Dave B., Migliaccio I., Gutierrez M. C., Wu M. F., Chamness G. C., Wong H., Narasanna A., Chakrabarty A., Hilsenbeck S. G., Huang J., Rimawi M., Schiff R., Arteaga C., Osborne C. K., Chang J. C., Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2overexpressing locally advanced breast cancers Journal of Clinical Oncology 2011 29 2 166 173
75. Nagata Y., Lan K. H., Zhou X., Tan M., Esteva F. J., Sahin A. A., Klos K. S., Li P., Monia B. P., Nguyen N. T., Hortobagyi G. N., Hung M. C., Yu D., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 2004 6 2 117 127 (Pubitemid 39485684)
76. Tokunaga E., Kimura Y., Mashino K., Oki E., Kataoka A., Ohno S., Morita M., Kakeji Y., Baba H., Maehara Y., Activation of PI3K/Akt signaling and hormone resistance in breast cancer Breast Cancer 2006 13 2 137 144
77. Christodoulou C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., Gogas H., Razis E., Skarlos D. V., Fountzilas G., Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer: phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation Oncology 2009 76 4 275 285
78. Esteva F. J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J. S., Sahin A. A., Hortobagyi G. N., Yu D., PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer American Journal of Pathology 2010 177 4 1647 1656
79. Haas-Kogan D. A., Prados M. D., Tihan T., Eberhard D. A., Jelluma N., Arvold N. D., Baumber R., Lamborn K. R., Kapadia A., Malec M., Berger M. S., Stokoe D., Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib Journal of the National Cancer Institute 2005 97 12 880 887 (Pubitemid 41417939)
80. Mellinghoff I. K., Wang M. Y., Vivanco I., Haas-Kogan D. A., Zhu S., Dia E. Q., Lu K. V., Yoshimoto K., Huang J. H. Y., Chute D. J., Riggs B. L., Horvath S., Liau L. M., Cavenee W. K., Nagesh Rao P., Beroukhim R., Peck T. C., Lee J. C., Sellers W. R., Stokoe D., Prados M., Cloughesy T. F., Sawyers C. L., Mischel P. S., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors The New England Journal of Medicine 2005 353 19 2012 2024 (Pubitemid 41609094)
81. Prados M. D., Chang S. M., Butowski N., Deboer R., Parvataneni R., Carliner H., Kabuubi P., Ayers-Ringler J., Rabbitt J., Page M., Fedoroff A., Sneed P. K., Berger M. S., McDermott M. W., Parsa A. T., Vandenberg S., James C. D., Lamborn K. R., Stokoe D., Haas-Kogan D. A., Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma Journal of Clinical Oncology 2009 27 4 579 584
82. Nigro C. L., Monteverde M., Riba M., Lattanzio L., Tonissi F., Garrone O., Heouaine A., Gallo F., Ceppi M., Borghi F., Comino A., Merlano M., Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer International Journal of Oncology 2010 37 5 1219 1228
83. O'Toole D., Couvelard A., Rebours V., Zappa M., Hentic O., Hammel P., Levy P., Bedossa P., Raymond E., Ruszniewski P., Molecular markers associated with response to chemotherapy in gastroentero-pancreatic neuroendocrine tumors Endocrine-Related Cancer 2010 17 4 847 856
84. Sos M. L., Koker M., Weir B. A., Heynck S., Rabinovsky R., Zander T., Seeger J. M., Weiss J., Fischer F., Frommolt P., Michel K., Peifer M., Mermel C., Girard L., Peyton M., Gazdar A. F., Minna J. D., Garraway L. A., Kashkar H., Pao W., Meyerson M., Thomas R. K., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Research 2009 69 8 3256 3261
85. Uramoto H., Shimokawa H., Hanagiri T., Kuwano M., Ono M., Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer. In press
86. Hildebrandt M. A. T., Yang H., Hung M. C., Izzo J. G., Huang M., Lin J., Ajani J. A., Wu X., Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy Journal of Clinical Oncology 2009 27 6 857 871
87. Vazquez F., Devreotes P., Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction Cell Cycle 2006 5 14 1523 1527 (Pubitemid 44091972)
88. Molina J. R., Morales F. C., Hayashi Y., Aldape K. D., Georgescu M. M., Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation Cancer Research 2010 70 17 6697 6703
89. Takahashi Y., Morales F. C., Kreimann E. L., Georgescu M. M., PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling EMBO Journal 2006 25 4 910 920 (Pubitemid 43292451)
90. Lazar C. S., Cresson C. M., Lauffenburger D. A., Gill G. N., The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface Molecular Biology of the Cell 2004 15 12 5470 5480 (Pubitemid 39564739)
91. Vivanco I., Rohle D., Versele M., Iwanami A., Kuga D., Oldrini B., Tanaka K., Dang J., Kubek S., Palaskas N., Hsueh T., Evans M., Mulholland D., Wolle D., Rajasekaran S., Rajasekaran A., Liau L. M., Cloughesy T. F., Dikic I., Brennan C., Wu H., Mischel P. S., Perera T., Mellinghoff I. K., The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation Proceedings of the National Academy of Sciences of the United States of America 2010 107 14 6459 6464
92. Wong E. V., Kerner J. A., Jay D. G., Convergent and divergent signaling mechanisms of growth cone collapse by ephrinA5 and slit2 Journal of Neurobiology 2004 59 1 66 81 (Pubitemid 38391809)
93. Brisbin S., Liu J., Boudreau J., Peng J., Evangelista M., Chin-Sang I., A role for C. elegans Eph RTK signaling in PTEN regulation Developmental Cell 2009 17 4 459 469
94. Bussolati B., Deambrosis I., Russo S., Deregibus M. C., Camussi G., Altered angiogenesis and survival in human tumor-derived endothelial cells FASEB Journal 2003 17 9 1159 1161
95. Trimboli A. J., Cantemir-Stone C. Z., Li F., Wallace J. A., Merchant A., Creasap N., Thompson J. C., Caserta E., Wang H., Chong J. L., Naidu S., Wei G., Sharma S. M., Stephens J. A., Fernandez S. A., Gurcan M. N., Weinstein M. B., Barsky S. H., Yee L., Rosol T. J., Stromberg P. C., Robinson M. L., Pepin F., Hallett M., Park M., Ostrowski M. C., Leone G., Pten in stromal fibroblasts suppresses mammary epithelial tumours Nature 2009 461 7267 1084 1091
96. Fosbrink M., Niculescu F., Rus V., Shin M. L., Rus H., C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1 Journal of Biological Chemistry 2006 281 28 19009 19018 (Pubitemid 44035404)
97. Nakao T., Shiota M., Tatemoto Y., Izumi Y., Iwao H., Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling Journal of Pharmacological Sciences 2007 105 4 334 341
98. Zheng H., Dai T., Zhou B., Zhu J., Huang H., Wang M., Fu G., SDF-1 /CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway Atherosclerosis 2008 201 1 36 42
99. Tarnawski A. S., Pai R., Tanigawa T., Matysiak-Budnik T., Ahluwalia A., PTEN silencing reverses aging-related impairment of angiogenesis in microvascular endothelial cells Biochemical and Biophysical Research Communications 2010 394 2 291 296
100. Cao J., Schulte J., Knight A., Leslie N. R., Zagozdzon A., Bronson R., Manevich Y., Beeson C., Neumann C. A., Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity EMBO Journal 2009 28 10 1505 1517
101. Connor K. M., Subbaram S., Regan K. J., Nelson K. K., Mazurkiewicz J. E., Bartholomew P. J., Aplin A. E., Tai Y. T., Aguirre-Ghiso J., Flores S. C., Melendez J. A., Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation Journal of Biological Chemistry 2005 280 17 16916 16924 (Pubitemid 41389151)
102. de Luca A., Sanna F., Sallese M., Ruggiero C., Grossi M., Sacchetta P., Rossi C., De Laurenzi V., Di Ilio C., Favaloro B., Methionine sulfoxide reductase A down-regulation in human breast cancer cells results in a more aggressive phenotype Proceedings of the National Academy of Sciences of the United States of America 2010 107 43 18628 18633
103. Bedard K., Krause K. H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology Physiological Reviews 2007 87 1 245 313 (Pubitemid 46209993)
104. Garrido-Urbani S., Jemelin S., Deffert C., Carnesecchi S., Basset O., Szyndralewiez C., Heitz F., Page P., Montet X., Michalik L., Arbiser J., Regg C., Krause K. H., Imhof B., Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPAR mediated mechanism PLoS ONE 2011 6 2, article e14665
105. Church J. E., Qian J., Kumar S., Black S. M., Venema R. C., Papapetropoulos A., Fulton D. J. R., Inhibition of endothelial nitric oxide synthase by the lipid phosphatase PTEN Vascular Pharmacology 2010 52 5-6 191 198
106. Koistinen P., Siitonen T., Mntymaa P., Sily M., Kinnula V., Savolainen E. R., Soini Y., Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system Leukemia 2001 15 9 1433 1441 (Pubitemid 32785313)
107. Cai J., Ahmad S., Jiang W. G., Huang J., Kontos C. D., Boulton M., Ahmed A., Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells Diabetes 2003 52 12 2959 2968 (Pubitemid 37466866)
108. Kumar P., Ning Y., Polverini P. J., Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion Laboratory Investigation 2008 88 7 740 749 (Pubitemid 351896641)
109. Park M. J., Kwak H. J., Lee H. C., Yoo D. H., Park I. C., Kim M. S., Lee S. H., Chang H. R., Hong S. I., Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor Journal of Biological Chemistry 2007 282 42 30485 30496 (Pubitemid 350035224)
110. Bussolati B., Deregibus M. C., Camussi G., Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies Current Vascular Pharmacology 2010 8 2 220 232
111. Dempke W. C. M., Heinemann V., Resistance to EGF-R (erbB-1) and VEGF-R modulating agents European Journal of Cancer 2009 45 7 1117 1128
112. Alessi P., Leali D., Camozzi M., Cantelmo A., Albini A., Presta M., Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist European Cytokine Network 2009 20 4 225 234
113. Ueda S. I., Basaki Y., Yoshie M., Ogawa K., Sakisaka S., Kuwano M., Ono M., PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib Cancer Research 2006 66 10 5346 5353 (Pubitemid 43844960)
114. Shi Y. H., Bingle L., Gong L. H., Wang Y. X., Corke K. P., Fang W. G., Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells Pathology 2007 39 4 396 400 (Pubitemid 47221464)
115. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., Kay C., In H. U., Langdon S., Goryanin I., Harrison D. J., Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab Cancer Research 2009 69 16 6713 6720
116. Negri F. V., Bozzetti C., Lagrasta C. A., Crafa P., Bonasoni M. P., Camisa R., Pedrazzi G., Ardizzoni A., PTEN status in advanced colorectal cancer treated with cetuximab British Journal of Cancer 2010 102 1 162 164
117. Martinelli E., Troiani T., Morgillo F., Rodolico G., Vitagliano D., Morelli M. P., Tuccillo C., Vecchione L., Capasso A., Orditura M., De Vita F., Eckhardt S. G., Santoro M., Berrino L., Ciardiello F., Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells Clinical Cancer Research 2010 16 20 4990 5001
118. Cohen E. E., Davis D. W., Karrison T. G., Seiwert T. Y., Wong S. J., Nattam S., Kozloff M. F., Clark J. I., Yan D. H., Liu W., Pierce C., Dancey J. E., Stenson K., Blair E., Dekker A., Vokes E. E., Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study The Lancet Oncology 2009 10 3 247 257
119. Engelman J. A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Reviews Cancer 2009 9 8 550 562
120. Marone R., Cmiljanovic V., Giese B., Wymann M. P., Targeting phosphoinositide 3-kinasemoving towards therapy Biochimica et Biophysica Acta 2008 1784 1 159 185
121. Anai S., Goodison S., Shiverick K., Iczkowski K., Tanaka M., Rosser C. J., Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts Human Gene Therapy 2006 17 10 975 984 (Pubitemid 46076739)
122. Lee J. S., Lee J. H., Poo H., Kim M. S., Lee S. H., Sung M. H., Kim C.